Global Archives – Page 20 of 25 – Treatment Action Group

Good COPs or Bad COPs: Promoting Interventions for Coinfections and AIDS in 2020 PEPFAR Country Operational Plans (COPs)

January 22, 2020
Dorrit Walsh

On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.

Sanofi Withdraws Two Patent Applications on Life-Saving Tuberculosis Prevention Drugs in Europe and in Indonesia

January 22, 2020
Dorrit Walsh

Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.

HIV & Aging

December 17, 2019
Chad Cipiti

A resource listing of articles, reports, websites, and ongoing clinical trials related to HIV and aging.

Cover of Tuberculosis Research Funding Trends 2005-2018

2019 Report on TB Research Funding Trends

December 10, 2019
Dorrit Walsh

TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.

Treatment Action Group Applauds Indian TB Activists in Opposing Patents for Critical TB Prevention Drugs

December 5, 2019
Dorrit Walsh

Treatment Action Group (TAG) applauds the legal actions undertaken by our colleagues from the Delhi Network of Positive People (DNP+) and tuberculosis (TB) survivor and activist Ganesh Acharya of Mumbai, with support from the Third World Network (TWN), contesting two patent applications on combinations of two decades-old TB medicines filed in India by French pharmaceutical company Sanofi.

Clinical Trials for People with Suboptimal Immune Reconstitution Despite HIV Suppression

November 16, 2019
Chad Cipiti

Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age.

Story: American Gene Technologies HIV Gene Therapy

November 8, 2019
Dorrit Walsh

November 2019 Examples of media coverage: Gene Tech Company Claims to Have Found a Cure for HIV/AIDS – NewNowNext, November 8, 2019 Researchers believe they’ve found the cure for HIV/AIDS – Pink News, November 8, 2019 Research Lab Believes They Have HIV/AIDS Cure – Instinct Magazine,…

Protestors Demand Cepheid Halve the Price of GeneXpert TB Tests to US$5

October 31, 2019
Dorrit Walsh

The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

Activist Guide to Hepatitis C Virus Diagnostics

October 31, 2019
Chad Cipiti

The purpose of this new publication is to provide information for you and your community. The Activist Guide aims to provide a deeper focus on diagnosis with updated information about the steps and different technologies involved in diagnosing a person with hepatitis C.

Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson

October 31, 2019
Dorrit Walsh

Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.